Skip to main content

Table 1 Characteristics of study participants in the discovery and replication cohorts

From: Epigenome-wide association study identifies DNA methylation markers for asthma remission in whole blood and nasal epithelium

  Discovery cohort Lifelines EGEA
PersA (n = 49) ClinR (n = 54) ComR (n = 20) PersA (n = 99) ClinR (n = 25) Healthy (n = 636) PersA (n = 106) ClinR (n = 15) ComR (n = 3)
Characteristics at last visit
 Age at remission status, years 49.8 (48.5; 51.3) 50.5 (48.3; 57.6) 50.5 (48.4; 59.8) 46.9 (40.7;50.7) 43.2 (35.7;50.3) 46.3 (39.2;52.9) 52.6 (36.7; 61.4) 49.2 (36.7; 57.6) 30.5 (28.2; 59.1)
 Male, n (%) 31 (63.3%) 37 (68.5%) 15 (75.0%) 58 (58.6%) 10 (40.0%) 384 (60.4%) 49 (46.7%) 7 (46.7%) 1 (33.3%)
 Duration of follow-up, years 39 (38;40.5) 39 (37; 42) 39 (37;41)     11.3 (10.7; 12.1) 11.6 (10.7; 12.2) 11.6 (10.0; 12.7)
 Current-smoking, n (%) 4 (8.2%) 8 (14.8%) 2 (10.0%) 27 (27.3%) 14 (56.0%) 207 (32.5%) 10 (9.5%) 2 (13.3%) 1 (33.3%)
 Ex-smoking, n (%) 13 (26.5%) 18 (33.3%) 7 (35.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 35 (33.3%) 5 (33.3%) 0
 Never-smoking, n (%) 32 (65.3%) 28 (51.9%) 11 (55.0%) 72 (72.7%) 11 (44.0%) 429 (67.5%) 60 (57.1%) 8 (53.3%) 2 (66.7%)
 ICS, n (%) 31 (63.3%) 0 0 48 (48.5%) 0 (0.0%) 0 (0.0%) 72 (70.6%) 0 0
 Allergic rhinitis, n (%) 33 (67.3%) 30 (55.6%) 9 (45.0%) 59 (59.6%) 13 (52.0%) 123 (19.3%) 70 (67.3%) 11 (73.3%) 2 (66.7%)
 BMI 25.7 (23.7; 28.5) 26.8 (23.7; 28.3) 26.0 (22.8; 28.6) 25.7 (22.9;28.0) 26.0 (23.7;29.6) 25.8 (23.6;28.1) 23.9 (22.4; 27.5) 22.5 (19.9; 28.0) 22.0 (19.9; 22.4)
 FEV1% pred 80.6 (71.1; 91.9) 90.2 (82.9; 104.7) 101.8 (85.9; 110.0) 81.2 (70.9;91.6) 87.1 (74.0;93.4) 101.5 (96.1;108.7) 87.0 (71.7; 98.4) 95.2 (87.5; 107.2) 97.5 (90.7; 121.5)
 FVC% pred 94.2 (88.4; 103.7) 101.7 (95.2; 111.5) 106.6 (101.2; 115.9) 94.1 (85.8;102.2) 100.3 (90.4;109.2) 104.0 (97.5;111.4) 98.5 (84.8; 108.9) 95.2 (86.9; 106.1) 96.3 (86.9; 119.2)
 FEV1/FVC 0.67 (0.60; 0.72) 0.72 (0.68; 0.75) 0.72 (0.68; 0.76) 0.67 (0.62;0.76) 0.67 (0.62;0.76) 0.79 (0.75;0.83) 0.69 (0.61; 0.77) 0.81 (0.78; 0.82) 0.80 (0.80; 0.91)
Characteristics at baseline
 Age, years 10.0 (9.0; 11.0) 11.0 (9.0; 17.5) 11.5 (9.8; 15.8)     40.6 (25.7; 48.7) 37.0 (26.0; 46.0) 18.9 (18.8; 46.4)
 FEV1% pred 76.6 (67.4; 84.0) 77.1 (67.5; 83.8) 78.1 (73.5; 83.7)     81.7 (66.2; 95.9) 90.6 (82.0; 103.0) 82.0 (80.1; 122.9)
 FVC% pred 88.8 (84.0; 96.1) 88,3 (80.9; 95.3) 88.9 (79.8; 96.5)     95.5 (83.7; 104.3) 86.4 (81.9; 100.6) 84.5 (70.1; 118.8)
 FEV1/FVC 0.73 (0.64; 0.78) 0.73 (0.66; 0.79) 0.77(0.66; 0.80)     0.70 (0.63; 0.80) 0.86 (0.82; 0.89) 0.86 (0.83; 0.96)
 Start asthma before age 16, n (%) 48 (98.0%) 50 (92.6%) 19 (95.0%) 59 (62.1%) 18 (81.8%)   52 (49.5%) 8 (53.3%) 2 (66.7%)
  1. Continuous data are presented as median (25th percentile; 75th percentile), category data are presented as number (percentage)
  2. Italic values represent significant differences compared with persistent asthma with P < 0.05 in the discovery cohort
\